World's Best Scientists 2026 revealed!

D-Index & Metrics

Discipline name D-Index World Ranking Current World Ranking National Ranking Current National Ranking Publications Citations
Medicine 110 5419 5088 532 508 429 69015

Mahesh K. B. Parmar publications per year

The chart shows the history of publications by Mahesh K. B. Parmar between 1985 and 2026, highlighting the no. of papers published in each year and offering an overview of the publication velocity of this scholar. Mahesh K. B. Parmar published across 42 years, from 1985 to 2026, averaging 13 papers a year. Output peaked at 49 publications in 2023. 24 of the 545 publications appeared in the last two years.

No. of publications
10 20 30 40
Bar chart. Horizontal axis: year, 1985 to 2026. Vertical axis: number of publications, 0 to 49. Peak 49 publications in 2023. 1985: 1 publication 1986: 0 publications 1987: 0 publications 1988: 1 publication 1989: 3 publications 1990: 3 publications 1991: 2 publications 1992: 5 publications 1993: 3 publications 1994: 10 publications 1995: 6 publications 1996: 11 publications 1997: 10 publications 1998: 7 publications 1999: 7 publications 2000: 7 publications 2001: 6 publications 2002: 8 publications 2003: 8 publications 2004: 7 publications 2005: 12 publications 2006: 10 publications 2007: 10 publications 2008: 15 publications 2009: 14 publications 2010: 5 publications 2011: 22 publications 2012: 17 publications 2013: 23 publications 2014: 19 publications 2015: 30 publications 2016: 32 publications 2017: 22 publications 2018: 12 publications 2019: 21 publications 2020: 25 publications 2021: 28 publications 2022: 27 publications 2023: 49 publications 2024: 23 publications 2025: 20 publications 2026: 4 publications
1985 2026

545 publications in total across all disciplines

View publications per year as a table
Mahesh K. B. Parmar: publications per year, 1985 to 2026
Year Publications
1985 1
1986 0
1987 0
1988 1
1989 3
1990 3
1991 2
1992 5
1993 3
1994 10
1995 6
1996 11
1997 10
1998 7
1999 7
2000 7
2001 6
2002 8
2003 8
2004 7
2005 12
2006 10
2007 10
2008 15
2009 14
2010 5
2011 22
2012 17
2013 23
2014 19
2015 30
2016 32
2017 22
2018 12
2019 21
2020 25
2021 28
2022 27
2023 49
2024 23
2025 20
2026 4
Total 545
Download as CSV

Mahesh K. B. Parmar publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Mahesh K. B. Parmar sits on this spectrum.

No. of scientists
200 400 600 800
Bar chart with 86 bars. Horizontal axis: publications, 101–120 to 1,796+. Vertical axis: number of scientists, 0 to 922. Most scientists, 922, have 341–360 publications. The last bar groups every scientist with 1,796 publications or more. The highlighted bar, 421–440 publications, is where this scientist sits. 101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101–120 publications 1,796+

This scientist: 429 publications — 45th percentile

45% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

View publications distribution as a table
Number of Medicine scientists by publication count, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
Publications Scientists This scientist
101–120 5
121–140 26
141–160 73
161–180 155
181–200 230
201–220 363
221–240 487
241–260 545
261–280 722
281–300 768
301–320 834
321–340 895
341–360 922
361–380 838
381–400 861
401–420 918
421–440 806 429
441–460 771
461–480 751
481–500 713
501–520 617
521–540 610
541–560 537
561–580 504
581–600 509
601–620 396
621–640 386
641–660 371
661–680 340
681–700 336
701–720 307
721–740 259
741–760 230
761–780 228
781–800 217
801–820 204
821–840 186
841–860 177
861–880 155
881–900 139
901–920 145
921–940 116
941–960 133
961–980 91
981–1,000 96
1,001–1,020 77
1,021–1,040 70
1,041–1,060 63
1,061–1,080 77
1,081–1,100 49
1,101–1,120 54
1,121–1,140 49
1,141–1,160 51
1,161–1,180 35
1,181–1,200 39
1,201–1,220 26
1,221–1,240 37
1,241–1,260 36
1,261–1,280 27
1,281–1,300 32
1,301–1,320 28
1,321–1,340 17
1,341–1,360 30
1,361–1,380 28
1,381–1,400 17
1,401–1,420 21
1,421–1,440 15
1,441–1,460 12
1,461–1,480 12
1,481–1,500 18
1,501–1,520 14
1,521–1,540 17
1,541–1,560 15
1,561–1,580 6
1,581–1,600 2
1,601–1,620 12
1,621–1,640 11
1,641–1,660 8
1,661–1,680 5
1,681–1,700 5
1,701–1,720 10
1,721–1,740 12
1,741–1,760 14
1,761–1,780 6
1,781–1,795 5
1,796+ 100
Download as CSV

Mahesh K. B. Parmar D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Mahesh K. B. Parmar sits on this spectrum.

No. of scientists
250 500 750 1,000
Bar chart with 75 bars. Horizontal axis: D-Index, 70–71 to 217+. Vertical axis: number of scientists, 0 to 1,027. Most scientists, 1,027, have 82–83 D-Index. The last bar groups every scientist with 217 D-Index or more. The highlighted bar, 110–111 D-Index, is where this scientist sits. 70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70–71 D-Index 217+

This scientist: 110 D-Index — 73rd percentile

73% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

View D-Index distribution as a table
Number of Medicine scientists by D-index, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
D-Index Scientists This scientist
70–71 226
72–73 391
74–75 574
76–77 730
78–79 891
80–81 972
82–83 1,027
84–85 1,003
86–87 960
88–89 970
90–91 922
92–93 839
94–95 808
96–97 779
98–99 668
100–101 611
102–103 630
104–105 513
106–107 541
108–109 445
110–111 429 110
112–113 399
114–115 393
116–117 318
118–119 302
120–121 287
122–123 255
124–125 256
126–127 252
128–129 230
130–131 179
132–133 168
134–135 163
136–137 159
138–139 134
140–141 134
142–143 118
144–145 109
146–147 106
148–149 74
150–151 79
152–153 80
154–155 87
156–157 57
158–159 74
160–161 69
162–163 60
164–165 53
166–167 39
168–169 42
170–171 32
172–173 39
174–175 40
176–177 28
178–179 19
180–181 23
182–183 31
184–185 18
186–187 20
188–189 22
190–191 13
192–193 21
194–195 12
196–197 12
198–199 14
200–201 15
202–203 13
204–205 10
206–207 8
208–209 4
210–211 12
212–213 11
214–215 10
216 4
217+ 98
Download as CSV

Overview

Mahesh K. B. Parmar is affiliated with University College London in the United Kingdom, focusing primarily on medical research. Their work spans several main fields and subfields, indicating a concentration on areas related to oncology and clinical trials.

The main field of study associated with Parmar's work is Medicine, with a total of 231 publications. Within this broad field, their subfields of study include:

  • Pulmonary and Respiratory Medicine (85 publications)
  • Statistics and Probability (52 publications)
  • Oncology (34 publications)
  • Radiology, Nuclear Medicine and Imaging (22 publications)
  • Reproductive Medicine (19 publications)

Parmar has explored various key topics in their research, notably:

  • Prostate Cancer Treatment and Research (88 publications)
  • Statistical Methods in Clinical Trials (66 publications)
  • Prostate Cancer Diagnosis and Treatment (42 publications)
  • Ovarian cancer diagnosis and treatment (32 publications)
  • Health Systems, Economic Evaluations, Quality of Life (30 publications)
  • Cancer Genomics and Diagnostics (24 publications)
  • Radiopharmaceutical Chemistry and Applications (22 publications)

Their recent publications include the following works, which have appeared in established medical journals:

  • "Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial," 2021, The Lancet
  • "A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19," 2020, New England Journal of Medicine
  • "Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial," 2020, The Lancet
  • "Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data," 2020, The Lancet
  • "Lung cancer mortality reduction by LDCT screening: UKLS randomised trial results and international meta-analysis," 2021, The Lancet Regional Health - Europe

Frequent co-authors collaborating with Parmar include:

  • Matthew R. Sydes (46 joint publications)
  • Noel W. Clarke (43 joint publications)
  • Nicholas D. James (39 joint publications)
  • Gerhardt Attard (26 joint publications)
  • Adrian Cook (19 joint publications)

The primary publication venues for Parmar's work are journals that focus on oncology and clinical trial research. These include:

  • Journal of Clinical Oncology (15 publications)
  • The Lancet Oncology (9 publications)
  • Annals of Oncology (9 publications)
  • Trials (7 publications)
  • Clinical Trials (7 publications)

Best Publications

  • Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints.

    Mahesh K. B. Parmar;Valter Torri;Lesley Stewart

  • Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study

    Hashim U Ahmed;Hashim U Ahmed;Ahmed El-Shater Bosaily;Ahmed El-Shater Bosaily;Louise C. Brown;Rhian Gabe

  • A phase 3 trial of bevacizumab in ovarian cancer.

    Timothy J Perren;Ann Marie Swart;Jacobus Pfisterer;Jonathan A Ledermann

  • Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial

    David Sebag-Montefiore;Richard J. Stephens;Robert Steele;John Monson

  • Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy

    Nicholas D. James;Johann S. de Bono;Melissa R. Spears;Noel W. Clarke

  • Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects.

    Patrick Royston;Mahesh K. B. Parmar

  • Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

    Nicholas D. James;Nicholas D. James;Matthew R. Sydes;Noel W. Clarke;Malcolm David Mason

  • Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial

    Phil Quirke;Phil Quirke;Robert Steele;John Monson;Robert Grieve

  • Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial

    Sean Kehoe;Jane Hook;Matthew Nankivell;Gordon C Jayson

  • Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial.

    Ian J Jacobs;Ian J Jacobs;Ian J Jacobs;Usha Menon;Andy Ryan;Aleksandra Gentry-Maharaj

  • International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: Long-Term Results of the BA06 30894 Trial

    Gareth Griffiths;Reginald Hall;Richard Sylvester;Derek Raghavan

  • Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.

    Christopher C Parker;Nicholas D James;Christopher D Brawley;Noel W Clarke

  • Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome

    Patrick Royston;Mahesh K B Parmar

  • Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial

    David P Dearnaley;Matthew R Sydes;John D Graham;Edwin G Aird

  • Reducing Uncertainties About the Effects of Chemoradiotherapy for Cervical Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data From 18 Randomized Trials

    Claire Vale;Jayne F. Tierney;Lesley A. Stewart;Mark Brady

  • Survival Analysis: A Practical Approach

    David Machin;Yin Bun Cheung;Mahesh K. B. Parmar

  • Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.

    Amit M. Oza;Adrian D. Cook;Jacobus Pfisterer;Andrew Embleton

  • Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial

    Michele Saunders;Stanley Dische;Ann Barrett;Angela Harvey

  • Bayesian Approaches to Randomized Trials

    David J. Spiegelhalter;Laurence S. Freedman;Mahesh K. B. Parmar

  • Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: Results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)

    Usha Menon;Aleksandra Gentry-Maharaj;Rachel Hallett;Andy Ryan

Frequent Co-Authors

Matthew R. Sydes
Matthew R. Sydes University College London
Nicholas D. James
Nicholas D. James Institute of Cancer Research
Noel W. Clarke
Noel W. Clarke University of Salford
Malcolm David Mason
Malcolm David Mason Cardiff University
Ian Jacobs
Ian Jacobs University of New South Wales
David P. Dearnaley
David P. Dearnaley Institute of Cancer Research
Patrick Royston
Patrick Royston University College London
Chris Parker
Chris Parker Institute of Cancer Research
Usha Menon
Usha Menon University College London
Stephen W. Duffy
Stephen W. Duffy Queen Mary University of London

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medical careers in the USA isn’t limited to becoming a doctor—numerous online degree pathways are available for those seeking flexible options. Registered nurses can upgrade their credentials through rn to bsn programs, which often offer coursework with minimal or no on-site clinical requirements, making them accessible for working professionals.

Those aiming for leadership or advanced practice roles may consider pursuing the shortest dnp programs online, which provide a compact curriculum focused on quick completion. There are even shortest dnp program options designed for efficiency, ideal for nurses eager to achieve a terminal degree without a lengthy time commitment.

For individuals starting their careers, fast track medical programs such as Licensed Practical Nurse (LPN) routes enable entry into the healthcare workforce in less time—using a flexible online format. These related pathways provide modern, efficient alternatives for advancing or starting a medical career in the USA.

Best Scientists Citing Mahesh K. B. Parmar

Trending Scientists

Recently Published Articles